Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Cellular senescence
Research brief

USP8–ACSL4 ferroptosis and senescence-like changes in chicken granulosa cells

In chicken ovarian follicular granulosa cells, the abstract reports that USP8 raises ACSL4 protein levels and promotes ferroptosis, which is associated with a senescence-like phenotype; ACSL4 knockdown reversed these effects. [1]

Automatic summary · not editorially reviewed

The key findings

  1. In chicken follicular granulosa cells, loss- and gain-of-function assays indicated that USP8 positively modulates ferroptosis. [1]

  2. USP8 regulates ACSL4 ubiquitination and proteasomal stability, increasing ACSL4 protein abundance and enhancing ACSL4-dependent ferroptosis. [1]

  3. ACSL4 knockdown reversed the ferroptosis and senescent phenotypes caused by USP8 dysregulation, but the abstract says in vivo validation is still needed. [1]

The source at a glance

Study type / format
Abstract of a laboratory cell study
Population / context
Chicken ovarian follicular granulosa cells
Summary based on
Study abstract
Original publication
October 5, 2026

USP8 and ferroptosis in chicken granulosa cells

The abstract describes ferroptosis as an iron-dependent cell death triggered by lipid peroxidation and notes that its role in avian reproduction is largely unclear. The authors tested the deubiquitinating enzyme USP8 in chicken follicular granulosa cells using loss- and gain-of-function assays. They report that USP8 positively modulates ferroptosis, shown by altered cell viability, glutathione depletion, higher malondialdehyde and reactive oxygen species levels, and different expression of FSP1, SLC7A11 and NCOA4.

Supporting source [1]

ACSL4 stability and senescence-like markers

Mechanistically, the abstract states that USP8 regulates ACSL4 ubiquitination and proteasomal stability, increasing ACSL4 protein abundance and thereby enhancing ACSL4-dependent ferroptosis. Functional analyses further report that USP8-promoted ferroptosis is associated with a senescence-like phenotype, marked by upregulation of P16, P21 and P53 and prominent G1-phase cell cycle arrest. Notably, ACSL4 knockdown effectively reversed the ferroptosis and senescent phenotypes caused by USP8 dysregulation.

Supporting source [1]

Proposed USP8-ACSL4 axis and open in vivo questions

The authors summarize their work as identifying a USP8-ACSL4-ferroptosis-senescence axis that may control granulosa cell fate and follicular atresia in chickens. They suggest USP8 and ACSL4 could be explored as potential targets for preserving granulosa cell function. The abstract itself states this remains to be validated in vivo, so the findings are from cell experiments and do not establish effects on whole birds or on lifespan.

Supporting source [1]

How to interpret this

Abstract only; the full text was not reviewed. Findings come from cell experiments in chickens, and the authors state that in vivo validation remains to be done.

Based on the study abstract; the full paper, tables and supplementary data were not reviewed.

Source & supporting passages

[1]
USP8 promotes ferroptosis-associated senescence-like phenotype in chicken ovarian follicular granulosa cells via ACSL4.

Zhu Y, Han S, Zhang H, Wu K, Ren P, Zhang A. · europepmc.org · October 5, 2026

Read the quoted passagesIn the language of the original source
  1. Finding 1 ↑

    USP8 positively modulates granulosa cell ferroptosis
  2. Finding 2 ↑

    USP8 regulates ACSL4 ubiquitination and proteasomal stability
  3. Finding 3 ↑

    ACSL4 knockdown effectively reversed the ferroptosis

AI-assisted summary with linked source passages. No independent editorial or clinical review.

Our editorial method

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…